TIGIT and liver cancer: The mRNA expression levels of immune checkpoint-related genes were significantly higher in the high-risk group than in the low-risk group, especially for immune checkpoint-related genes commonly used in liver cancer immunotherapy, including (PD-L1, PDCD1LG2, PDCD1, TIGIT, TIM-3, CTLA4).